Medexus Pharmaceuticals Inc (MDP) Fair Value & Analysis
Healthcare · CA · Market cap C$126M
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from C$3.23 to C$2.90 (−10.2%) since Jun 23, 2026. Share price +31.4% over the past month.
Price vs Fair Value (12 months)
12‑month range C$2.03 – C$4.05 · fair‑value band C$1.91 – C$3.89 · the C$4.05 price screens above the C$2.90 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Medexus Pharmaceuticals Inc (MDP) currently trades at C$4.05, while our model-based Fair Value estimate is C$2.90 — implying the stock looks roughly 28.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Medexus Pharmaceuticals Inc generated revenue of C$99.4M at a net margin of -0.3%. Revenue declined 15.6% year over year. It earns a return on equity of -0.6%. Net debt stands at C$13.2M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxac…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medexus Pharmaceuticals Inc reported revenue of C$108M in FY2025 versus C$79.7M in FY2021, a compound +8.0%/yr. Reported net income was C$2.2M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medexus Pharmaceuticals Inc (MDP) undervalued?
What is the fair value of MDP?
What is the quality score of MDP?
What is the revenue of Medexus Pharmaceuticals Inc (MDP)?
What is the net profit margin of MDP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.